XNYS
INSP
Market cap1.93bUSD
Oct 08, Last price
66.69USD
1D
-1.13%
1Q
28.84%
IPO
172.54%
Name
Inspire Medical Systems Inc
Chart & performance
P/E
13.26
P/S
2.11
EPS
5.03
Div yield, %
—
Shrs. gr., 5y
2.68%
Rev. gr., 5y
51.21%
Revenues
912m
+13.60%
Net income
145m
+171.77%
CFO
117m
-10.19%
Dividend
Jan 09, 20089 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.
Key people
Marilyn Carlson Nelson
Independent Chairman of the Board · since 2016
Timothy P. Herbert
President, Chief Executive Officer, Director · since 2007
Richard Buchholz
Chief Financial Officer · since 2014
Steven Jandrich
Chief Compliance Officer, Vice President of Human Resources · since 2017
Randall A. Ban
Chief Commercial Officer · since 2019
Jerry C. Griffin
Independent Director · since 2008
Independent Director · since 2014
Independent Director · since 2017
Independent Director · since 2008
Independent Director · since 2008
Legal address
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Headquarters
5500 Wayzata Boulevard
Suite 1600
Golden Valley, MN 55416
US
Suite 1600
Golden Valley, MN 55416
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||